Parallel Advisors LLC Raises Position in United Therapeutics Co. (NASDAQ:UTHR)

Parallel Advisors LLC grew its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 18.2% during the second quarter, according to its most recent filing with the SEC. The firm owned 937 shares of the biotechnology company’s stock after acquiring an additional 144 shares during the period. Parallel Advisors LLC’s holdings in United Therapeutics were worth $298,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. SG Americas Securities LLC raised its holdings in United Therapeutics by 176.2% in the first quarter. SG Americas Securities LLC now owns 14,315 shares of the biotechnology company’s stock worth $3,288,000 after purchasing an additional 9,133 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in United Therapeutics by 19.0% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 25,686 shares of the biotechnology company’s stock valued at $5,901,000 after acquiring an additional 4,100 shares during the period. Comerica Bank boosted its stake in United Therapeutics by 5.9% during the first quarter. Comerica Bank now owns 165,911 shares of the biotechnology company’s stock worth $38,113,000 after acquiring an additional 9,244 shares in the last quarter. QRG Capital Management Inc. grew its holdings in United Therapeutics by 12.4% in the second quarter. QRG Capital Management Inc. now owns 15,321 shares of the biotechnology company’s stock worth $4,880,000 after purchasing an additional 1,692 shares during the period. Finally, Campbell & CO Investment Adviser LLC increased its stake in shares of United Therapeutics by 163.8% during the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,245 shares of the biotechnology company’s stock valued at $1,813,000 after purchasing an additional 5,120 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Insider Activity

In related news, Director Raymond Dwek sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $325.35, for a total transaction of $1,626,750.00. Following the completion of the sale, the director now directly owns 1,750 shares in the company, valued at $569,362.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $313.91, for a total value of $1,130,076.00. Following the transaction, the chief executive officer now owns 130 shares of the company’s stock, valued at $40,808.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Raymond Dwek sold 5,000 shares of United Therapeutics stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $325.35, for a total value of $1,626,750.00. Following the transaction, the director now directly owns 1,750 shares in the company, valued at $569,362.50. The disclosure for this sale can be found here. Insiders sold 114,522 shares of company stock valued at $37,671,474 in the last quarter. 12.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

UTHR has been the topic of a number of analyst reports. HC Wainwright reissued a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. TD Cowen increased their target price on United Therapeutics from $270.00 to $350.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Oppenheimer upped their price target on shares of United Therapeutics from $400.00 to $575.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 28th. LADENBURG THALM/SH SH lowered shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 1st. Finally, UBS Group upped their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, July 8th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $350.36.

United Therapeutics Price Performance

Shares of UTHR opened at $342.59 on Thursday. The firm has a fifty day simple moving average of $337.74 and a two-hundred day simple moving average of $289.59. The firm has a market cap of $15.24 billion, a PE ratio of 16.20, a P/E/G ratio of 1.25 and a beta of 0.57. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $366.08.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, July 31st. The biotechnology company reported $5.85 EPS for the quarter, missing analysts’ consensus estimates of $6.33 by ($0.48). The firm had revenue of $714.90 million for the quarter, compared to analysts’ expectations of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The firm’s revenue was up 19.8% compared to the same quarter last year. During the same quarter last year, the company posted $5.24 EPS. On average, equities analysts anticipate that United Therapeutics Co. will post 24.86 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.